Vaccine Storage and Handling are critical aspects of the vaccine supply chain, ensuring that vaccines remain safe, effective, and potent from the time they are manufactured until they are administered to individuals. Proper storage and handling procedures are essential to maintain the stability and integrity of vaccines and prevent their degradation or spoilage. Vaccines are sensitive biological products that can lose their potency if exposed to inappropriate storage conditions, such as extreme temperatures, light, or improper handling. Therefore, vaccines must be stored and transported within a specific temperature range recommended by the manufacturer, typically between 2°C and 8°C (36°F to 46°F) for most vaccines.
Specialized vaccine storage units, such as refrigerators and freezers, are used to maintain the recommended temperature range and protect vaccines from temperature fluctuations. These units should be equipped with temperature monitoring devices, such as digital data loggers or thermometers, to continuously monitor and record the temperature to ensure compliance with storage requirements. Vaccine storage units should also be properly organized to prevent overcrowding and ensure adequate air circulation around the vaccines. During transport, vaccines should be packed in insulated containers with temperature-monitoring devices to maintain the recommended temperature range. Cold chain management practices, such as using cold packs or ice packs, are employed to keep vaccines within the appropriate temperature range during transit. Proper vaccine handling procedures are also essential to prevent contamination and maintain vaccine integrity. Healthcare providers should adhere to strict hygiene practices, such as handwashing and wearing gloves, when handling vaccines to minimize the risk of contamination.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom